First Trimester Risk Assessment Based on Ultrasound and Cell-free DNA vs Combined Screening

Aneuploidy Clinical Trial

Official title:

First Trimester Risk Assessment Based on Ultrasound and Cell-free DNA vs Combined Screening: Women's Experience

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04077060
• Other study ID #: 209/19
• Status: Completed
• Phase: N/A
• Start date: August 26, 2019
• Est. completion date: February 15, 2020

Study information

• Verified date: February 2020
• Source: Federico II University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There is an ongoing debate regarding how cell-free DNA (cfDNA) screening can best be incorporated into current prenatal screening algorithms for chromosomal abnormalities.

Test performance of cfDNA has been shown to be better that first-trimester combined screening (FTCS). However, the cost of the cfDNA testing is considered too high to adopt as first line screening. Moreover, FTCS includes a detailed ultrasound examination of the fetus with nuchal translucency (NT) measurement that allows for early detection of fetal abnormalities.

An approach in which every woman are offered an early anatomy scan along with cfDNA may also be a reasonable option. Recently a randomized controlled trial, including 1,518 women with singleton pregnancy undergoing first-trimester screening, compared the screening performance of FTCS with an approach that uses the combination of a detailed ultrasound examination and cfDNA analysis. The trial showed that first-trimester risk assessment for trisomy 21 that includes a detailed ultrasound examination along cfDNA was associated with a significant reduction in the false-positive rate compared with FTCS. This approach obviates the need for maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A in screening for fetal aneuploidy.

Despite robust evidence on the very high detection rate of cfDNA in detecting trisomy 21, literature is lacking on data regarding women's experience and emotional well-being and satisfaction after test-results of women offered cfDNA compared to those offered FTCS.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: February 15, 2020
• Est. primary completion date: January 15, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Pregnant women with singleton gestations

• =12 6/7 weeks of gestation

• Normal ultrasound examination at the time of randomization

• >18 <45 years

• Crown-rump length (CRL) <84 mm at the time of randomization

Exclusion Criteria:

• Multiple gestations, including vanishing twins

• >12 6/7 weeks of gestation

• Ectopic pregnancy

• Abnormal ultrasound examination at the time of first prenatal visit

• Women who are unconscious, severly ill, mentally handicapped, or under the age of 18 years.

• Women who have already planned for invasive prenatal testing, e.g. for a history of prior child or pregnancy with chromosomal or genetic abnormalities

• CRL >84mm at the time of randomization

Related Conditions & MeSH terms

• Aneuploidy

Intervention

Diagnostic Test:
• NIPT
Women randomized in the intervention group will be offered cfDNA screening, along with an early detailed anatomy scan, including nuchal measurement, at 11-13 weeks of gestation. cfDNA analysis will include a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. NIPT will be performed at the time of randomization or after if gestational age at randomization < 9 6/7 weeks of gestation. Women in both groups will be given oral counseling by obstetricians and will be counseled about test procedures, reporting time, test sensitivity and specificity, and the necessity to confirm abnormal screening results with invasive testing.
• combined screening
Control group includes the standard of care. In our department, first-trimester risk assessment is performed routinely at 11-13 weeks of gestation by FTCS as per standard of care. FTCS includes crown-rump length, NT measurements, and a detailed ultrasound examination based on ISUOG guidelines. All operators who perform this examination are certified by the UK Fetal Medicine Foundation (FMF). A specific risk for aneuploidy is not calculated if NT measurement is >3.5 mm or if fetal anomaly is identified. These cases are deemed to be at a very high risk for chromosomal abnormalities and are offered invasive testing.

Locations

Country	Name	City	State
Italy	Gabriele Saccone	Napoli

Sponsors (1)

Lead Sponsor	Collaborator
Federico II University

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	reassurance	women will be asked about three questions, with up to 35 point for each question. 1) are you reassured about the test? 2) are you sure the test is correct? 3) test give me certain reassurance about the syndrome of my child	at the time of screening test
Primary	Anxiety	anxiety test assessed by State-Trait Anxiety Inventory (STAI)	at the time of screening test
Primary	Satisfaction of the pregnant women	women will be asked if retrospectively they are happy with the assigned screening test as post-test satisfaction questionnaire: Not all applicable (5 points); Hardly applicable (10 points); Somewhat applicable (20 points); Very much applicable (35 points)	11-13 weeks of gestation
Primary	False positive rate	False positive rate for any trosomy and for trisomy 21	1 week after test
Primary	Anxiety	anxiety test assessed by The Pregnancy-Related Anxiety Questionnaire (PRAQ-R)	at the time of screening test